Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Taiwan University Hospital |
---|---|
Information provided by: | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00173628 |
Evaluate the autoantibodies, such as glutamic acid decarboxylase (GAD65), tyrosine phosphatase (IA-2 or ICA125), islet autoantibodies (IAA) and other associated autoimmune autoantibodies: microsomal antibodies, thyroglobulin antibodies, gastric parietal cell antibodies in patients with type 1 DM.
Condition | Intervention |
---|---|
Type 1 Diabetes |
Procedure: blood drawing |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Defined Population, Retrospective/Prospective Study |
Estimated Enrollment: | 150 |
Study Start Date: | January 1990 |
Estimated Study Completion Date: | December 2006 |
Type 1 diabetes mellitus (DM) is a common disease in pediatric endocrine clinic and epidemiological studies showed the racial variation in the incidence, with the highest of 35 cases per 100000 in Finland. The incidence of type 1 DM in Taiwan is reported to be 1.5 per 100000 for the population less than 30 years old. While the diagnosis is made, the residual islet cell function is only about 20% of normal population. Therefore, the principle therapy in these patients is insulin therapy lifelong. The pathogenesis of type 1 diabetes mellitus is multifactorial and controversial, involving the genetic and environmental factors. Type 1 DM is an autoimmune disease, which is T cell mediated islet cell destruction. Ninety percent of patients with type 1 DM express at least one of the autoantibodies to the islet. Antibodies to glutamic acid decarboxylase 65 (GAD65) were observed in 60-80% of such patients, which were considered the most important autoantigens. The autoantibodies disappeared successively after diagnosis and decreased in concentrations over time, but titers of antibodies to GAD65 had been observed fluctuated in patients with type 1 DM. The prevalence of GAD antibodies, insulin autoantibodies, IA-2 (tyrosine phosphatase) were reported as 45-67%, 23-67% and 49%, respectively in Taiwan.
Other associated autoimmune disease, such as autoimmune thyroiditis were reported as 13-24%. Such differences may be caused by the enrolling criteria and different age population. Therefore, we want to elucidate the role of autoantibodies in the pathogenesis of type 1 DM.
Ages Eligible for Study: | up to 20 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria: - pediatric patients with type 1 diabetes
Contact: Yi-Ching Tung, MD | 886-2-23123456 ext 5130 | dtped004@yahoo.com.tw |
Taiwan | |
National Taiwan University Hospital | Recruiting |
Taipei, Taiwan | |
Contact: Yi-Ching Tung, MD 886-2-23123456 ext 5130 dtped004@yahoo.com.tw |
Principal Investigator: | Yi-Ching Tung, MD | National Taiwan University Hospital |
Study ID Numbers: | 9461700824 |
Study First Received: | September 12, 2005 |
Last Updated: | December 20, 2005 |
ClinicalTrials.gov Identifier: | NCT00173628 History of Changes |
Health Authority: | Taiwan: Department of Health |
Autoimmune Diseases Metabolic Diseases Autoantibodies Diabetes Mellitus, Type 1 Diabetes Mellitus |
Endocrine System Diseases Diabetes Mellitus Type 1 Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
Autoimmune Diseases Metabolic Diseases Immune System Diseases Diabetes Mellitus, Type 1 |
Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders |